ArticleMedicine2026
Causal association of genetically predicted 1400 blood metabolites with inflammatory bowel disease risk: A Mendelian randomization study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We utilized an unbiased 2-sample Mendelian randomization approach to investigate the potential causal relationship between 1400 human blood metabolites and the risk of inflammatory bowel disease (IBD). Exposure data were sourced from the largest metabolome-based genome-wide association study (mGWAS), which included 8299 individuals from Canada. The results were primarily derived from a meta-analysis of genome-wide association studies (GWAS) involving 25,042 patients and 34,915 healthy controls, with additional data from a European GWAS database consisting of 12,882 IBD cases and 21,770 healthy controls. The main analysis employed the inverse variance weighted model, alongside Mendelian randomization-Egger regression and the weighted median method for supplementary analysis. Heterogeneity and pleiotropy sensitivity analyses were also conducted to ensure result robustness. The replication analysis of the inverse variance weighted (IVW) method identified 53 blood metabolites significantly associated with IBD risk (P <.05). Following thorough analysis and sensitivity testing, 5 blood metabolites were found to have a significant causal relationship with IBD (P <.05). Specifically, 2 metabolites were linked to an increased risk of IBD: Oleoyl-linoleoyl-glycerol (18:1-18:2) [2] to linoleoyl-arachidonoyl-glycerol (18:2-20:4)[2] ratio (OR = 1.1174, 95% CI = 1.0697-1.1674, P = 6.3693 × 10-7) and N-palmitoyl-heptadecasphingosine (d17:1/16:0) levels (OR = 1.0981, 95% CI = 1.0318-1.1687, P = 3.2196 × 10-3). The other 3 metabolites, including 1-stearoyl-2-arachidonoyl-GPI (18:0/20:4) levels (OR = 0.8864, 95% CI = 0.8375-0.9382, P = 3.1373 × 10-5), 1-palmitoyl-2-stearoyl-gpc (16:0/18:0) levels (OR = 0.8667, 95% CI = 0.8076-0.9301, P = 7.1645 × 10-5), and acetylcarnitine levels (biocrates platform) (OR = 0.8754, 95% CI = 0.8075-0.9490, P = 1.2329 × 10-3), were associated with decreased IBD risk. Notably, no reverse causality was observed for any of these 5 metabolites. In conclusion, 5 blood metabolites were identified as causally associated with IBD, including 2 increasing and 3 decreasing disease risk. These findings can not only provide a new perspective for the pathogenesis of IBD but may also provide a theoretical basis for its prevention and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.